Related Experiment Video
Updated: Jul 5, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Plasma myeloperoxidase is related to the severity of coronary artery disease
Ovünç Düzgünçinar1, Bünyamin Yavuz, Tuncay Hazirolan
1Department of Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Objective:
It has been shown that the main apolipoprotein of HDL, Apo A-1, is subjected to nitration by myeloperoxidase (MPO) and this oxidative modification renders HDL proatherogenic. The aim of this study is to evaluate the relationship between plasma MPO levels, and the severity of coronary artery disease.
Methods And Results:
Forty-eight patients with coronary artery narrowing and 30 control subjects were enrolled in this study. The severity of the disease was assessed by Gensini scoring after angiography. MPO concentrations were determined by using an enzyme immunoassay. A subgroup of 30 patients underwent computerized tomography to determine the calcium load of coronary arteries. Plasma MPO levels were found significantly higher in patients with coronary artery disease than controls (4.27 [1.60 to 42.43] ng/mL vs. 2.93 [1.00 to 9.25] ng/mL, P = 0.002). MPO was positively correlated with both Gensini (r = 0.228, P = 0.044) and coronary calcium scores (r = 0.433, P = 0.017). The atherosclerotic burden was more strongly correlated with MPO levels than the traditional markers such as total cholesterol and HDL.
Conclusions:
We found that MPO levels were elevated in patients with coronary artery disease and this increase correlated with the extent and severity of atherosclerosis. Although it is a preliminary study with a relatively small group of subjects, we suggest that MPO might be evaluated as a new marker indicating the presence and severity of coronary artery disease.
Insights
Elevated myeloperoxidase (MPO) levels are linked to coronary artery disease severity. This study suggests MPO may serve as a novel biomarker for assessing atherosclerosis extent and presence.
Area of Science:
- Cardiovascular Research
- Biomarker Discovery
- Atherosclerosis Research
Background:
- Myeloperoxidase (MPO) modifies apolipoprotein A-1 (Apo A-1), a key HDL component, inducing a proatherogenic effect.
- Oxidative modification of HDL by MPO plays a role in the development of atherosclerosis.
Purpose of the Study:
- To investigate the association between plasma MPO levels and the severity of coronary artery disease (CAD).
- To explore MPO as a potential biomarker for CAD presence and extent.
Main Methods:
- Enrolled 48 CAD patients and 30 controls.
- Assessed CAD severity using Gensini scoring and coronary calcium scores via CT angiography.
- Quantified plasma MPO concentrations using enzyme immunoassay.
Main Results:
- Plasma MPO levels were significantly higher in CAD patients compared to controls (P = 0.002).
- MPO levels positively correlated with both Gensini score (r = 0.228, P = 0.044) and coronary calcium score (r = 0.433, P = 0.017).
- MPO showed a stronger correlation with atherosclerotic burden than traditional markers like total cholesterol and HDL.
Conclusions:
- Elevated MPO levels are observed in patients with coronary artery disease.
- MPO levels correlate with the extent and severity of atherosclerosis.
- MPO may be a valuable new marker for indicating the presence and severity of CAD.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:30Peripheral Artery Disease I: Introduction
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:21Myocarditis I: Introduction